Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Ratios

Olema Pharmaceuticals (OLMA) Long-Term Debt Issuances (2020)

Olema Pharmaceuticals (OLMA) has 1 years of Long-Term Debt Issuances data on record, last reported at $3.0 million in Q1 2020.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $3.0 million in Q1 2020 year-over-year; TTM through Dec 2020 was $3.0 million, a N/A change, with the full-year FY2020 number at $3.0 million, changed N/A from a year prior.
Long-Term Debt Issuances reached $3.0 million in Q1 2020 per OLMA's latest filing.
Over the last five years, Long-Term Debt Issuances for OLMA hit a ceiling of $3.0 million in Q1 2020 and a floor of $3.0 million in Q1 2020.